176 related articles for article (PubMed ID: 20425063)
1. Does choice of antidiabetes therapy influence macrovascular outcomes?
Zarich SW
Curr Diab Rep; 2010 Feb; 10(1):24-31. PubMed ID: 20425063
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic agents and cardiovascular risk in type 2 diabetes.
Zarich SW
Nat Rev Endocrinol; 2009 Sep; 5(9):500-6. PubMed ID: 19636325
[TBL] [Abstract][Full Text] [Related]
3. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
4. Potential of glucose-lowering drugs to reduce cardiovascular events.
Zarich SW
Curr Diab Rep; 2009 Feb; 9(1):87-94. PubMed ID: 19192430
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
6. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
[TBL] [Abstract][Full Text] [Related]
7. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
9. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
Rosenstock J; Marx N; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Bluhmki E; Patel S; Johansen OE; Woerle HJ
Diab Vasc Dis Res; 2013 Jul; 10(4):289-301. PubMed ID: 23449634
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.
Yandrapalli S; Jolly G; Horblitt A; Pemmasani G; Sanaani A; Aronow WS; Frishman WH
Cardiol Rev; 2020; 28(4):177-189. PubMed ID: 32282393
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
[TBL] [Abstract][Full Text] [Related]
14. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
Santamarina M; Carlson CJ
BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Home P
Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
[TBL] [Abstract][Full Text] [Related]
16. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
Chrysant SG
Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
[TBL] [Abstract][Full Text] [Related]
17. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
[TBL] [Abstract][Full Text] [Related]
18. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of diabetes in metabolic syndrome].
Pelikánova T
Vnitr Lek; 2009; 55(7-8):637-45. PubMed ID: 19731868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
